article thumbnail

Moderna partners with Life Edit for mRNA gene editing therapies

Pharmaceutical Technology

The collaboration will combine the mRNA platform of Moderna with the gene editing technologies suite, including the base editing capabilities of Life Edit for the development of curative therapies to treat challenging genetic diseases. Life Edit will get an upfront payment and is eligible for potential milestone payments.

article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

A nitrogen-binding drug, its global sales were $292m in 2021, as per GlobalData. According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. In order to find the specific RNA sequences for a genetic disease, the biotech is using an AI- and machine learning-based approach.

RNA 245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Meet the industry: Who’s at Drug Discovery 2023?

Drug Discovery World

When it comes to the technologies driving drug discovery, she thinks that the ability to specifically edit regions of the genome using CRISPR/Cas9 is particularly revolutionary. Dr Fraser, on the other hand, thinks cell and gene therapy (CGT) is the new frontier of disease treatment innovation.

Drugs 59
article thumbnail

Top 10 Fastest Growing Biotech Companies in 2023

XTalks

Its remarkable success is primarily credited to its innovative mRNA platform, which is dedicated to developing therapies for a wide spectrum of medical conditions, such as infectious diseases, cancer, cardiovascular ailments and rare diseases.

Genetics 111